• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    CG Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    3/28/25 7:15:08 AM ET
    $CGON
    Get the next $CGON alert in real time by email
    8-K
    0001991792false00019917922025-03-282025-03-28

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): March 28, 2025

     

     

    CG Oncology, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-41925

    37-1611499

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    400 Spectrum Center Drive

    Suite 2040

     

    Irvine, California

     

    92618

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (949) 409-3700

     

    N/A

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, par value $0.0001 per share

     

    CGON

     

    The Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


     

    Item 2.02 Results of Operations and Financial Condition.

     

    On March 28, 2025, CG Oncology, Inc. issued a press release announcing its financial results for the year and quarter ended December 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

    In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing.

     

     

     


     

    Item 9.01 Financial Statements and Exhibits.

    (d)

    Exhibits

     

     

     

    Exhibit No.

    Description

     

     

    99.1

    Press release, dated March 28, 2025

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

     


     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

    CG Oncology, Inc.

     

     

    Date: March 28, 2025

    By: /s/ Josh Patterson

     

    Name: Josh Patterson

     

    Title: General Counsel and Chief Compliance Officer

     

     


    Get the next $CGON alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CGON

    DatePrice TargetRatingAnalyst
    5/2/2025$41.00Overweight
    Analyst
    4/16/2025$23.00Sector Perform
    Scotiabank
    1/7/2025Buy
    TD Cowen
    10/24/2024$60.00Buy
    UBS
    9/23/2024$66.00Outperform
    RBC Capital Mkts
    8/28/2024$65.00Buy
    ROTH MKM
    6/28/2024$65.00Buy
    BofA Securities
    2/20/2024$75.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $CGON
    Financials

    Live finance-specific insights

    See more
    • CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting

      - Robust 24-month complete response rate of 42.3% by K-M for cretostimogene monotherapy in BOND-003 Cohort C – - 58.3% of patients showed durable complete responses by K-M at 24 months – - 97.3% of all treated patients remained free from progression to MIBC at 24 months– - 91.6% of responders remained cystectomy-free at 24 months – - No Grade 3 or greater treatment-related adverse events or deaths reported – - Strong initial Cohort P data reported 90.5% high-grade recurrence-free survival at 3 and 9 months by K-M – - Company will host a conference call and webcast at 8 a.m. EDT on Monday, April 28, 2025 - IRVINE, Calif., April 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:C

      4/26/25 4:10:03 PM ET
      $CGON
    • CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025

      IRVINE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced it will host a conference call and live webcast at 8:00 am ET on April 28, 2025, to discuss results from the Phase 3 BOND-003 trial of cretostimogene monotherapy in high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) to be presented on April 26, 2025, at a Plenary Session at the American Urological Association (AUA) Annual Meeting in Las Vegas, Nevada. Individuals can access the webcast via the link on

      4/24/25 8:00:00 AM ET
      $CGON
    • CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates

      - Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated CORE-008 Clinical Trial of Cretostimogene Monotherapy in High-Risk BCG-Naïve (Cohort A) and BCG-Exposed (Cohort B) NMIBC - - Late-Breaking Clinical and First Translational Data from BOND-003 Cohort C Presented at the 40th Annual European Association of Urology Congress - - Completed Oversubscribed $238 Million Follow-on Public Equity Offering that Extends Expected Runway into the First Half of 2028 - IRVINE, Calif., March 28, 2025 (GLOBE NEWS

      3/28/25 7:00:00 AM ET
      $CGON

    $CGON
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Decheng Capital Global Life Sciences Fund Iv, L.P. bought $7,600,000 worth of shares (400,000 units at $19.00) (SEC Form 4) (Amendment)

      4/A - CG Oncology, Inc. (0001991792) (Issuer)

      4/9/24 7:08:23 PM ET
      $CGON

    $CGON
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Analyst initiated coverage on CG Oncology with a new price target

      Analyst initiated coverage of CG Oncology with a rating of Overweight and set a new price target of $41.00

      5/2/25 8:14:21 AM ET
      $CGON
    • Scotiabank initiated coverage on CG Oncology with a new price target

      Scotiabank initiated coverage of CG Oncology with a rating of Sector Perform and set a new price target of $23.00

      4/16/25 8:09:10 AM ET
      $CGON
    • TD Cowen initiated coverage on CG Oncology

      TD Cowen initiated coverage of CG Oncology with a rating of Buy

      1/7/25 7:46:13 AM ET
      $CGON

    $CGON
    SEC Filings

    See more

    $CGON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by CG Oncology Inc.

      SCHEDULE 13G/A - CG Oncology, Inc. (0001991792) (Subject)

      5/15/25 4:32:25 PM ET
      $CGON
    • SEC Form 10-Q filed by CG Oncology Inc.

      10-Q - CG Oncology, Inc. (0001991792) (Filer)

      5/13/25 8:30:21 AM ET
      $CGON
    • CG Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - CG Oncology, Inc. (0001991792) (Filer)

      5/13/25 8:15:10 AM ET
      $CGON
    • Director Post Leonard E exercised 1,000 shares at a strike of $0.60 and sold $28,000 worth of shares (1,000 units at $28.00) (SEC Form 4)

      4 - CG Oncology, Inc. (0001991792) (Issuer)

      5/22/25 4:15:05 PM ET
      $CGON
    • Director Post Leonard E exercised 1,000 shares at a strike of $0.60 and sold $30,760 worth of shares (1,000 units at $30.76) (SEC Form 4)

      4 - CG Oncology, Inc. (0001991792) (Issuer)

      4/29/25 4:15:03 PM ET
      $CGON
    • SEC Form 4 filed by Chief Executive Officer Kuan Arthur

      4 - CG Oncology, Inc. (0001991792) (Issuer)

      4/16/25 4:15:18 PM ET
      $CGON

    $CGON
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CG Oncology to Participate in the 2025 RBC Capital Markets Global Healthcare Conference

      IRVINE, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that management will participate in a fireside chat at the 2025 RBC Capital Markets Global Healthcare Conference in New York, NY on Tuesday, May 20, 2025, at 11:30 am ET. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.cgoncology.com. The webcast replay will be available after the conclusion of the live presentation for approximate

      5/15/25 8:00:00 AM ET
      $CGON
    • CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates

      - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal in Cohort P with 90.5% high-grade recurrence free survival at 3 and 9 months by K-M -- New enrollment completion date for Phase 3 PIVOT-006 in intermediate-risk non-muscle invasive bladder cancer (NMIBC) expected in the second half of 2025 -- Initiated CORE-008 Cohort CX evaluating the combination of cretostimogene and gemcitabine in patients with high-risk (HR) BCG-exposed NMIBC - IRVINE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical bi

      5/13/25 8:00:00 AM ET
      $CGON
    • SUO-CTC and CG Oncology Announce the 2025 Award Recipients for the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

      - Award recipients Honored at the American Urological Association's 2025 Annual Meeting - - Fellowship designed to support the development of outstanding clinical cancer research investigators to improve the understanding and treatment of NMIBC - SCHAUMBURG, Ill. and IRVINE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), a national alliance of leading academic and community based uro-oncologists, and CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced t

      5/1/25 8:00:00 AM ET
      $CGON

    $CGON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by CG Oncology Inc.

      SC 13G/A - CG Oncology, Inc. (0001991792) (Subject)

      11/12/24 2:30:47 PM ET
      $CGON
    • Amendment: SEC Form SC 13G/A filed by CG Oncology Inc.

      SC 13G/A - CG Oncology, Inc. (0001991792) (Subject)

      11/4/24 10:22:51 AM ET
      $CGON
    • SEC Form SC 13G filed by CG Oncology Inc.

      SC 13G - CG Oncology, Inc. (0001991792) (Subject)

      7/22/24 4:35:57 PM ET
      $CGON